LBA29 Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
| Autor: | Ray-Coquard, I.L., Leary, A., Pignata, S., Cropet, C., Martin, A.J. Gonzalez, Bogner, G., Yoshida, H., Vergote, I.B., Colombo, N., Maenpaa, J., Selle, F., Schmalfeldt, B., Scambia, G., Alia, E.M. Guerra, Lefeuvre-Plesse, C., Belau, A., Lortholary, A., Gropp-Meier, M., Pujade-Lauraine, E., Harter, P. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1396-S1397 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|